In a story appearing today (July 30) in the Wall Street Journal, the Food and Drug Administration is reported to be cracking down on companies whose sales representatives make improper statements about pharmaceutical products at medical conventions. According to the story, the FDA has cited pharmaceutical firms in at least nine recent cases for allowing representatives to make improper statements or presentations at exhibit booths. Monitoring booth conversations is a new development for the ...

Register for Complete Access (Valid Email Required)

By registering on MeetingsNet now, you'll not only unlock thePrinter-friendly, you'll also gain access to exclusive premium content.

Already registered? here.